Enalapril: Nursing Drug Guide, Angioedema & Hold Rules
Vasotec lowers blood pressure and supports heart-failure outcomes, but nurses must guard against angioedema (incidence higher in Black patients per labeling), first-dose hypotension when diuretics overlap, hyperkalemia, and acute kidney injury with NSAIDs or volume depletion—and discontinue immediately when pregnancy is detected.
The Vasotec boxed warning states that when pregnancy is detected, enalapril should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Separately, angioedema of the face, lips, tongue, glottis, or larynx—including fatal cases—has occurred with ACE inhibitors—including higher reported incidence in Black patients; discontinue immediately and escalate airway care when involvement threatens breathing. Serum potassium and renal function need periodic surveillance because RAS blockade predisposes to hyperkalemia and acute kidney injury, particularly with dehydration, NSAIDs, potassium supplements, potassium-sparing diuretics, or dual RAS inhibition.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every enalapril dose, reconcile pregnancy status, airway-threatening swelling, and whether a new diuretic or NSAID could trigger symptomatic hypotension or a creatinine/potassium jump—Vasotec labeling emphasizes supervised first doses when diuretics cannot be stopped.
Most common brand names
Enalapril is the generic name for this angiotensin-converting enzyme inhibitor. Common U.S. brand marketing uses Vasotec. Fixed-dose combinations with other antihypertensives exist in broader formularies; verify the precise product on each order because combination tablets may pair enalapril with agents such as a thiazide or a calcium channel blocker (for example combinations sometimes include amlodipine). Always trace both active ingredients through medication reconciliation rather than trusting look-alike bottle labels.
Why we give it — Indications
Vasotec prescribing information approves enalapril for hypertension (alone or with thiazide-type diuretics), symptomatic congestive heart failure (usually with diuretics and digitalis), and to slow progression of overt heart failure in asymptomatic left ventricular dysfunction (ejection fraction ≤35%). Nurses on medical–surgical units most often administer the antihypertensive tablet; cardiology and heart-failure teams manage titration in decompensated states per heart failure pathways.
| Use | Detail |
|---|---|
| Hypertension | Reduces blood pressure; may combine with thiazide-type diuretics when monotherapy is insufficient. |
| Heart failure (symptomatic) | Improves symptoms, increases survival, and decreases hospitalization frequency in trials cited in labeling (with diuretics ± digitalis). |
| Asymptomatic LV dysfunction | Decreases rate of overt heart failure development and heart-failure hospitalizations in patients with reduced ejection fraction. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Enalapril is absorbed and converted hepatically to enalaprilat, the primary ACE-blocking metabolite detailed in prescribing information. Inhibiting ACE reduces angiotensin II and aldosterone effects—producing vasodilation with modest serum potassium rises (hypertensive monotherapy trials report mean increases ≈0.2 mEq/L over 48 weeks per labeling). ACE also degrades bradykinin; whether elevated bradykinin contributes both to blood pressure lowering and to ACE inhibitor cough is discussed in labeling. Bradykinin excess is clinically linked to nuisance dry cough and overlaps mechanistically with angioedema vigilance pathways.
Dosing overview
Doses below reflect the reviewed Vasotec label; titrate strictly to clinician orders and to blood pressure plus renal-electrolyte response. Estimated GFR informs starting dose selections described in prescribing information (eGFR trends support monitoring alongside serum creatinine).
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption / onset | ≈60% oral absorption; peak enalapril ≈1 h; antihypertensive effect begins within about 1 h of a single dose with 24-h carryover | First-dose hypotension risk peaks when diuretics continue—align orthostatic vitals with MAR timing |
| Active metabolite peak | Enalaprilat peaks 3–4 h after oral enalapril maleate; food does not materially change overall exposure | Document whether patients take tablets with meals for consistent symptom tracking |
| Elimination | Primarily renal (~94% recovered as enalaprilat or enalapril); enalaprilat dialyzable | Renal impairment and dialysis timing affect accumulation—coordinate pharmacy when CrCl falls |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Identify pregnancy possibilities in patients of reproductive potential and verify aligned contraceptive or testing plans coordinated with prescribing teams
- Review baseline and recent renal function trajectory—especially when starting therapy, escalating dose, restarting after illness, or adding nephrotoxic or hyperkalemia-provoking drugs
- Screen for hypersensitivity histories to ACE inhibitors angioedema—even without prior ACE exposure per contraindications language
- Confirm whether interacting agents are present: NSAIDs, potassium supplements, potassium-sparing diuretics (for example concurrent spironolactone), dual RAS-blocking regimens (losartan or ARB combos), neprilysin inhibitors, lithium, immunosuppressant mTOR agents, oral hypoglycemic intensification predisposing hypoglycemia
Contraindications (FDA label summary)
- Hypersensitivity to enalapril or another ACE inhibitor
- History of angioedema including hereditary or idiopathic angioedema
- Combination with neprilysin inhibitor (example sacubitril)—do not start enalapril within 36 hours of switching from sacubitril/valsartan and vice versa
- Concurrent aliskiren with ACE inhibitors—including enalapril—in patients who have diabetes (label contraindication)
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| Loop diuretics, thiazide diuretics | Excessive blood pressure drops—especially shortly after initiating diuretics or escalating ACE dose | Take orthostatic vitals closely first two weeks and after dose tweaks; escalate symptomatic hypotension or oliguria |
| Potassium-retaining therapies | Combined aldosterone suppression plus spironolactone-type agents or supplementation elevates hyperkalemia incidence | Ensure scheduled laboratory follow-up potassium review; withhold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact |
| NSAID / COX-2 inhibitors | Reduced antihypertensive effect plus worsened renal impairment risk | Educate OTC avoidance without prescriber review; monitor creatinine and blood pressure pairing when unavoidable short courses emerge |
| Dual RAS inhibition | Higher renal dysfunction hypotension potassium disturbances | Scrutinize inpatient lists for simultaneous ACE ARB mineralocorticoid-direct renin blocker combinations violating policy; involve pharmacy early |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Vasotec tablets: 2.5 mg, 5 mg, 10 mg, and 20 mg (imprinted VASO strengths); swallow intact unless pharmacy directs otherwise
- May be taken with or without food per labeling
- Pharmacy may compound 1 mg/mL oral suspension from tablets per manufacturer directions for patients who cannot swallow—nurses administer pharmacy-prepared suspension only
- IV enalaprilat exists as a separate product—not interchangeable with oral Vasotec tablets on the MAR
Expected therapeutic response
- Blood pressures decline within two to four hours of individual doses achieving peak effects while sustaining twenty-four-hour control
- Combination with thiazide diuretics may blunt concurrent hypokalemia versus diuretics alone owing to tempered aldosterone signals
- Patients should articulate improved exercise tolerance contingent on cardiorespiratory comorbidity status once hypotension-mediated symptoms absent
Red flags — Stop and act
- Progressive airway-compromising lip swelling, tongue fullness, muffled speech, inspiratory difficulty—assume ACE inhibitor angioedema requiring immediate pathway activation
- Serum potassium climbing trend even before critical numeric threshold—coordinate repeat testing and cessation of potassium introductions
- New oliguria dizziness syncope collapsing perfusion pressures after initiating therapy or restarting post-acute illness referencing symptomatic orthostatic dizziness
- Creatinine elevations suggesting acute kidney injury attributable to RAS suppression volume depletion or renovascular physiology
- Life-threatening hypersensitivity manifestations consistent with dialysis membrane or venom-desensitization anaphylactoid reactions described in prescribing information—stop dialysis or procedure per protocol activate resuscitation resources
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dizziness, headache, cough | Hypertension trials: headache 5.2%, dizziness 4.3%, cough 1.3% (placebo-subtracted where listed); heart-failure trials: dizziness 7.9%, hypotension 6.7% | Teach positional caution after first doses; distinguish dry cough from angioedema; hold and escalate symptomatic hypotension |
| Anaphylactoid reactions dialysis membrane / desensitization context | Documented sentinel cases with ACE inhibitors undergoing specific high-flux dialysis or hymenoptera desensitization | Never minimize unusual intra-dialysis collapse—stop procedure treat supportively document medication class linkage |
| Severe cutaneous hepatic hematologic adverse events catalogued label | Stevens–Johnson erythema multiforme pancreatitis hemolytic anemia thrombocytopenia among postmarketing signal list | Immediately discontinue escalate laboratory evaluation when mucosal involvement bleeding infection stability compromise appear |
On a small screen, swipe or scroll sideways to see the full table.
Overdose management
Human enalapril overdosage data are limited in labeling. Animal lethality occurred at very high oral doses. The most likely human manifestation is hypotension; there is no specific reversal agent cited.
Recommended supportive therapies (label)
- Intravenous normal saline infusion for hypotension
- Enalaprilat may be removed by hemodialysis; peritoneal dialysis removed enalapril from neonatal circulation in labeling examples
- Supportive perfusion, airway, and electrolyte monitoring per institutional toxicology protocol
- Consult local poison control / toxicology services per facility protocol when ingestion amount or intent is uncertain
Consult local poisoning or toxicology services per institutional policy when intentional overdose ingestion volume remains uncertain—even though labeling describes no reversal agent analogous to opioids or acetaminophen pathways.
Look-alike / sound-alike and error prevention
- Vasotec versus lisinopril / benazepril / quinapril: ACE inhibitor names and tablet colors vary by manufacturer—barcode every dose
- Enalapril versus enalaprilat injection: oral prodrug is not the same MAR line as IV enalaprilat
- Strength jumps: 2.5 mg, 5 mg, 10 mg, and 20 mg triangle tablets (VASO imprint) sit adjacent in ADCs—witness high-risk strengths
- Combination products: confirm whether order references enalapril monotherapy versus fixed combination containing second antihypertensive class inadvertently duplicated elsewhere
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Swallow intact | Standard Vasotec tablets are intended orally intact; compounded suspension exists only via pharmacy-specific preparation—not ad hoc crushed tablets unless pharmacy validates stability. |
| Meal pairing | Eating shifts enalaprilat peak latency without prohibiting coexistence consistent meals—steady daily pattern assists timing vitals trending. |
| Orthostatics | Volume-depleted hospitalized patients merit lying-standing blood pressure coupling during initial therapy weeks aligning warning language. |
| Airway adjunct readiness | Because angioedema may involve laryngeal structures rapidly, bedside teams benefit confirming emergency airway equipment availability zones when initiating new RAS inhibitor courses high-risk phenotype. |
| Pharmacy escalation triggers | Uncertainty about breastfeeding safety neprilysin transition windows lithium co-therapy dosing or suspension compounding should route through pharmacist corroboration before administration finishes. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Vasotec labeling links second- and third-trimester fetal injury to renin-angiotensin inhibition (renal hypoperfusion, oligohydramnios-associated complications, neonatal renal dysfunction). Nursing priority is cessation as soon as pregnancy is recognized or reliably suspected plus coordinated obstetric and prescribing follow-up. |
| Chronic kidney disease / renovascular risk | People whose renal perfusion depends on angiotensin II (renovascular disease, decompensated heart failure, volume contraction) may develop abrupt creatinine rises or oliguria when ACE inhibition starts—coordinate hold rules and laboratory timing with nephrology or cardiology per prescriber. |
| Pediatrics | Antihypertensive effects established ages 1 month–16 years; not recommended in neonates or when pediatric GFR <30 mL/min/1.73 m². Starting dose 0.08 mg/kg (up to 5 mg) once daily per labeling. |
| Black ancestry monotherapy caveat | Vasotec labeling notes smaller average antihypertensive response with ACE monotherapy in Black patients versus non-Black patients, and reports higher angioedema incidence in Black patients—nurses prioritize airway teaching and never dismiss swelling because blood pressure response seems modest. |
| Lactation | LactMed cites low breastmilk concentrations with modeled infant ingestion under 0.14% maternal weight-adjusted doses predominantly enalaprilat whose oral bioavailability clinically trivial—overall infant risk expectation low individualized discussion remains standard. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness—labeling warns about symptomatic hypotension with volume depletion
- Serum creatinine and eGFR trends with electrolytes on the basic metabolic panel, including potassium
- Distinguish nuisance dry cough from progressive inspiratory distress, voice change, or swelling that may signal airway angioedema
- Blood glucose when antidiabetic therapy runs concurrently—labeling notes increased hypoglycemia risk, especially during the first month of combined use
Document
- Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
- Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and hypoglycemia vigilance when diabetes medicines overlap
- Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends
Patient teaching
- Discuss pregnancy planning—stop enalapril as soon as pregnancy is suspected or confirmed per the boxed warning
- Teach that facial, lip, or tongue swelling, noisy breathing, or swallowing difficulty means stop the drug and seek emergency care immediately—do not take another dose
- Do not start potassium supplements or potassium-containing salt substitutes without prescriber approval
- Report light-headedness, especially when standing; vomiting, diarrhea, heat exposure, and dehydration increase hypotension risk during early therapy
- Diabetic patients should monitor glucose more closely when ACE inhibitors are added—labeling warns of increased hypoglycemia risk with antidiabetic medicines
- Check with the care team before starting OTC NSAIDs such as ibuprofen—combined use can worsen renal function and blunt blood pressure control
The Hold Rule
Hold (clinician-aligned) dosing and escalate when:
- Pregnancy confirmed or suspected—discontinue immediately and notify the prescriber for obstetric follow-up
- Angioedema or any airway-threatening swelling of the face, lips, tongue, or throat—hold and escalate per emergency protocol
- Hyperkalemia, oliguria, or rising creatinine after dehydration, NSAID use, or dual RAS-blocking therapy—hold and clarify with prescriber/pharmacist
- Symptomatic hypotension, syncope, or shock until volume status and orders are reviewed
- Prohibited combinations on the MAR (dual RAS blockade, aliskiren with ACE inhibitor in diabetes, neprilysin inhibitor within 36-hour switch window, or suspected lithium toxicity)
Clinical practice integration and workflow
1. Stewardship checkpoints
- Barcode verify Vasotec strength before every administration pass
- Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change
- Screen admission medication lists for OTC renal stressors undocumented preadmission NSAID aspirin stacks
2. High-alert designation
Not universally classified institutional high-alertTreat enalapril with proportional vigilance analogous high-stakes cardiometabolic meds because fetal catastrophe airway angioedema and renal failure potentials exceed ordinary oral antihypertensive error tolerance.
3. Hold and question cues
- New tongue thickness lip asymmetry vocal changes—assume ACE inhibitor airway emergency until clarified
- Creatinine jump ≥30% clinician-defined institution thresholds after RAS initiation mandates hold clarification per policy
- Patient purchased OTC anti-inflammatory pills without informing team—coordinate pause teaching prescriber review
Teach-back prompts
- “Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face lip tongue airway difficulty emergency activation.)
- “Why should potassium salt substitutes worry your heart team?” (Patient references hyperkalemia coupling ACE inhibition.)
Pharmacist collaboration: Neprilysin sacubitril/valsartan transition windows NSAID unavoidable courses lithium dosing potassium binder coordination breastmilk counselling.
Prescriber / specialist: Resistant hypertension dialysis membrane planning angioedema recurrence pregnancy confirmation hyperkalemia refractory escalating renal insults unexplained hepatic enzyme cholestasis alerts.
🧠 Quick mental checklist
- Airway—is there progressing lip tongue voice change after today’s doses?
- Renal trajectory—Scr potassium sodium pairing volume status fair?
- Pregnancy possibility documentation contraception counseling complete?
- New NSAID potassium supplementation salt substitutes reviewed?
- If hypotensive after suspected overdose—is volume resuscitation pathway prepared though no antidote?
Enalapril NCLEX practice questions
Practice NCLEX-style clinical judgment practice for enalapril: use the case tabs (MAR, Labs, Vitals, Nursing notes) to judge first-dose hypotension with diuretics, angioedema escalation, SATA cue recognition, potassium/creatinine trend SATA, urgency matrix sorting, breastfeeding teaching MCQ, and overdose cloze focused on hypotension and hemodialysis—not a labeled antidote.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Vasotec (enalapril) 2.5 mg PO now—first inpatient ACE inhibitor dose (cardiology order)
- Furosemide 40 mg PO daily at 0800 (home dose continued on admission)
- Carvedilol 6.25 mg PO twice daily with meals
- BMP this morning: serum creatinine 1.55 mg/dL (admission day 1 was 1.28)
- Potassium 4.9 mEq/L; sodium 134 mEq/L
- BNP elevated on admission per chart (exact value in EHR)
- BP sitting 104/62 mm Hg, HR 92, RR 18, SpO₂ 95% on 2 L NC
- Reports lightheadedness when moving supine to chair; orthostatic set incomplete
- Weight down 1.8 kg since admission with decreasing pedal edema
- Admitted for heart failure exacerbation; patient asks why a “BP pill” is starting when pressure “already low”
- No lip or tongue swelling at 0830 assessment; prior ACE inhibitor intolerance not documented
- Preceptor reminds team Vasotec labeling requires supervised observation after first dose when diuretics continue
Answer key & rationale
Frequently asked questions
What is the most urgent ACE inhibitor complication nurses must not miss?
Angioedema involving the lips, tongue, glottis, or larynx can obstruct the airway—Vasotec labeling reports fatal reactions in some patients. Nurses should withhold further doses immediately on suspicion and coordinate airway-capable escalation per protocol until symptoms fully resolve.
Why does enalapril increase hyperkalemia risk?
Inhibiting the renin–angiotensin–aldosterone axis reduces aldosterone-mediated potassium elimination. Prescribing information recommends periodically monitoring potassium especially with renal impairment, diabetes mellitus, potassium-sparing drugs, supplemental potassium or potassium-containing salt substitutes, and overlapping RAS-blocking therapy.
What happens if pregnancy is detected?
Discontinue enalapril as soon as possible—the boxed warning states RAS-active drugs administered during pregnancy can injure or kill the fetus through oligohydramnios-related complications, neonatal renal failure, and related morbidity.
Is there an antidote for enalapril overdose?
No specific antidote is listed—the expected principal manifestation is hypotension managed with IV normal saline per Vasotec overdosage guidance. Enalaprilat may be removed by hemodialysis. Consult local poison control or toxicology services per institutional protocol when ingestion is intentional or dose is uncertain.
What does LactMed say about breastfeeding?
LactMed cites low milk levels with estimated maximum infant intake ≈0.16% of maternal weight-adjusted dose; no adverse effects were reported in four breastfed infants exposed to maternal enalapril 5–10 mg daily. Vasotec labeling still requires individualized prescriber discussion because serious infant reactions remain theoretically possible.
Why is the first enalapril dose with a diuretic high risk?
Patients on diuretics—especially after recent intensive diuresis—can develop marked hypotension, oliguria, or acute renal failure when ACE inhibition starts. Vasotec directs 2.5 mg under supervision for at least two hours (plus one additional stable hour) when diuretics cannot be stopped, or stopping the diuretic 2–3 days beforehand when feasible.
References
-
U.S. National Library of Medicine. Vasotec (enalapril hydrochloride) tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39631f1f-5d19-43c1-b504-bf56d991ed97
-
Drugs and Lactation Database (LactMed). Enalapril. Bethesda (MD): National Institute of Child Health and Human Development; updated 2024.https://www.ncbi.nlm.nih.gov/books/NBK500582/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.